OpenAI has acquired Orchestra Bio, a four-year-old startup that builds AI agents for the drug development industry, the company announced on its website. The terms of the deal were not disclosed, but Orchestra had reportedly raised around $20 million as of 2025 from investors including Andreessen Horowitz, Atria, and 8VC, according to TechCrunch.
The move marks OpenAI's latest step into life sciences, a vertical it has been quietly building out through Rosalind, its AI model for research. The acquisition is a classic example of how the biggest AI labs are moving deeper into major industries like pharma, either by partnering with startups or absorbing them before they become competitors.
Orchestra Bio and the Rosalind Workbench
Orchestra Bio's agents handle the operational details that slow down drug discovery: tracking finances, resolving scheduling conflicts with clinical trials, and managing the day-to-day logistics that biotech companies often struggle with. OpenAI says it is adding both Orchestra's team and its technology to Rosalind.
Rosalind itself is already finding traction in the industry. OpenAI claims Moderna and Novo Nordisk as customers for the model, giving it a foothold in a sector where AI is increasingly seen as a way to cut years off development timelines.
- Orchestra Bio: a four-year-old AI biotech software startup that creates AI agents for drug discovery operations.
- Rosalind: OpenAI's AI model for life sciences research.
- Rosalind Workbench: a tool designed to help researchers plan experiments and analyze results.
